Skip to main content
. 2021 Oct 9;101(1):131–137. doi: 10.1007/s00277-021-04682-x

Table 2.

Survival outcomes in the post-approval time frame

Post-approval ruxolitinib-unexposed (n = 1127) Post-approval ruxolitinib-exposed (n = 272)
Patients with valid death dates, n (%) 382 (33.9) 54 (19.9)
Median OS (95% CI), months 44.4 (37.3–62.0) NR (51.0–NR)
1-year survival rate (95% CI), % 72.5 (69.5–75.2) 82.3 (76.7–86.7)
2-year survival rate (95% CI), % 60.6 (56.9–64.0) 76.1 (69.2–81.7)

NR, not reached; OS, overall survival